Cloning

FDA Authorizes Simultaneous Stem Cell Trials for Parkinson’s

Retrieved on: 
Monday, June 21, 2021
Research, FDA, Clinical trials, Philanthropy, Stem cells, Other Health, Biotechnology, Health, Foundation, Science, Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Cell biology, Induced stem cells, Cloning, Mesenchymal stem cell, Stem-cell therapy, Cell therapy

This 60-patient trial is the second FDA clinical trial authorization in Parkinsons for HBSCRF, who already has a 24-patient double-blind placebo trial underway utilizing autologous adipose-derived mesenchymal stem cells.

Key Points: 
  • This 60-patient trial is the second FDA clinical trial authorization in Parkinsons for HBSCRF, who already has a 24-patient double-blind placebo trial underway utilizing autologous adipose-derived mesenchymal stem cells.
  • HBSCRF will become the first research organization in the U.S. to conduct simultaneous trials examining effects of administering the patients own cells (autologous) and donor cells (allogeneic) on the same disease condition.
  • We have to explore every facet of how adipose-derived mesenchymal stem cells act in this disease condition, says HBSCRF Founder Donna Chang.
  • Our primary research focus has always been on autologous stem cells, but in COVID, for example, when we ran three simultaneous studies in prevention and treatment, we encountered a situation where people needed cells but did not have their stem cells banked.

Yushangmei acquires American company Totally Green Inc. to accelerate its vision to establish an international expansion platform

Retrieved on: 
Tuesday, June 22, 2021
Branches of biology, Biology, Life sciences, Biotechnology, Cloning, Induced stem cells, Cell biology, Developmental biology, Stem cell

Pursuant to the Sale and Purchase Agreement, Yushangmei proposes to acquire and Totally Green intends to sell the controlling stake in the target company (or its holding company).

Key Points: 
  • Pursuant to the Sale and Purchase Agreement, Yushangmei proposes to acquire and Totally Green intends to sell the controlling stake in the target company (or its holding company).
  • Yushangmei owns a range of high-tech health products such as Fuhengbao, Miaoyiyan, and Jinshubao, which mainly focus on women's personal health care and are developed by self-dependent technology.
  • The company has cooperated intensively with the R&D institutions for high-tech female reproductive health product, stem cells,biomedicine and universities in Mainland China.
  • What's more, with the use of digitalized technology, e-commerce system platform is perfectly created, while online and offline businesses are highly integrated.

iQIYI Hosts M2VOC Challenge with 6 Papers Included in ICASSP2021

Retrieved on: 
Saturday, June 19, 2021
Branches of biology, Molecular biology, Biology, Asexual reproduction, Cloning, Cryobiology, Benchmark

M2VoC, an ICASSP2021 Signal Processing Grand Challenge, aimed at providing a common sizable dataset and a fair test bed for benchmarking voice cloning tasks.

Key Points: 
  • M2VoC, an ICASSP2021 Signal Processing Grand Challenge, aimed at providing a common sizable dataset and a fair test bed for benchmarking voice cloning tasks.
  • The M2VoC had two main tracks, including one for teams working from limited samples and one for very limited samples.
  • As the world's first Multi-speaker Multi-style Voice Cloning Challenge, M2VoC brought together leading teams from industry and academia at the cutting edge of voice cloning technology.
  • A total of 18 related papers were included in the Challenge, among which 6 papers were included in ICASSP2021.

Global Cell Isolation (Human Cells and Animal Cells) Market Research Report 2021-2026 - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 17, 2021
Health, Biotechnology, Branches of biology, Biology, Life sciences, Biotechnology, Cloning, Induced stem cells, Cell biology, Laboratory techniques, Stem cell, Cell isolation, Centrifugation, Stemcell Technologies

Cell isolation is a technique of isolating cells for diagnosis and analysis of a particular type of cell.

Key Points: 
  • Cell isolation is a technique of isolating cells for diagnosis and analysis of a particular type of cell.
  • The Global Cell Isolation Market has been segmented into product, cell type, source, technique, application, end-user, company and region.
  • Based on technique, the market is further fragmented into centrifugation-based cell isolation, surface-marker based cell isolation and filtration-based cell isolation, amongst which, centrifugation-based cell isolation segment occupied the largest market share in 2020 as it finds extensive applications in various end-user sectors such as academic institutes, research laboratories, etc.
  • Based on application, the market is further divided into biomolecule isolation, cancer research, stem cell research, in vitro diagnostics and others.

Brainstorm Announces Expansion of NurOwn® IP Portfolio with Grant and Allowance of Multiple Patents and Applications in Major Markets

Retrieved on: 
Tuesday, June 15, 2021
Branches of biology, Biology, Life sciences, Biotechnology, Cell biology, Stem cells, Cloning, Developmental biology, M cells, Cell therapy, Patent

"We continue to see success developing a comprehensive global patent portfolio for NurOwn and these latest patents further strengthen our overall IP position in major markets," said Chaim Lebovits, Chief Executive Officer of Brainstorm Cell Therapeutics.

Key Points: 
  • "We continue to see success developing a comprehensive global patent portfolio for NurOwn and these latest patents further strengthen our overall IP position in major markets," said Chaim Lebovits, Chief Executive Officer of Brainstorm Cell Therapeutics.
  • "The claims of these patents are the result of Brainstorm's world class expertise in applying cell therapy to treat neurodegenerative disorders.
  • They underscore the potential value of NurOwn as a novel treatment for diseases such as ALS and MS, which represent major unmet needs."
  • 2,937,305
    Details: Allowed claims cover a pharmaceutical composition comprising NurOwn (MSC-NTF cells, mesenchymal stem cells secreting neurotrophic factors)
    Patent #: US patent No.

Citius Pharmaceuticals Expands Scientific Advisory Board with Addition of Dr. John Laffey, Expert in Stem Cell and Gene Therapies for ARDS

Retrieved on: 
Tuesday, June 15, 2021
Branches of biology, Biology, Life sciences, Biotechnology, Cell biology, Cloning, Developmental biology, Stem cell, Acute respiratory distress syndrome

Each member of the board is a recognized key opinion leader (KOL) with extensive clinical trial expertise in the treatment of acute lung disorders.

Key Points: 
  • Each member of the board is a recognized key opinion leader (KOL) with extensive clinical trial expertise in the treatment of acute lung disorders.
  • His cutting-edge research into the use of gene and stem cell-based therapies to treat ARDS will provide Citius with an important perspective as we explore the potential of this exciting new therapeutic area.
  • Dr. Laffey's primary focus is on the investigation of therapeutic strategies for ARDS.
  • The current focus of his research is on the investigation of the therapeutic potential of gene and stem cell-based therapies for acute lung injury.

ElevateBio Announces Margo Roberts, Ph.D. Joins as Scientific Advisor for Company’s Immunotherapy Platform Expansion

Retrieved on: 
Thursday, June 10, 2021
Research, Genetics, Stem cells, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Branches of biology, Biology, Life sciences, Biotechnology, Induced stem cells, Stem cells, Emerging technologies, Cloning, Immunotherapy, Gene therapy, Induced pluripotent stem cell

ElevateBio, a cell and gene therapy technology company focused on powering transformative cell and gene therapies, today announced that Margo Roberts, Ph.D., has joined the company as a Strategic Scientific Advisor.

Key Points: 
  • ElevateBio, a cell and gene therapy technology company focused on powering transformative cell and gene therapies, today announced that Margo Roberts, Ph.D., has joined the company as a Strategic Scientific Advisor.
  • Dr. Roberts will provide her leading immunology research, drug discovery, and development expertise to the company as it builds out a comprehensive immunotherapy platform on behalf of its portfolio companies and strategic partners.
  • The company has built an initial technology stack, including gene editing, induced pluripotent stem cells, and protein, viral, and cellular engineering.
  • ElevateBio is headquartered in Cambridge, Mass, with ElevateBio BaseCamp located in Waltham, Mass.

Global Stem Cell Partnering Terms and Agreements 2010-2021 - Access 650 Deal Records - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 9, 2021
Biotechnology, Pharmaceutical, Health, Stem cells, Articles, Branches of biology, Biology, Biotechnology, Stem cells, Cell biology, Cloning, Science, technology, engineering, and mathematics

This report provides details of the latest Stem Cell agreements announced in the life sciences since 2010.

Key Points: 
  • This report provides details of the latest Stem Cell agreements announced in the life sciences since 2010.
  • The report takes the reader through a comprehensive review Stem Cell deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Stem Cell partnering deals.
  • A comprehensive series of appendices is provided organized by Stem Cell partnering company A-Z, stage of development, deal type, and therapy focus.
  • Global Stem Cell Partnering Terms and Agreements 2010-2021 provides the reader with the following key benefits:
    Insight into terms included in a Stem Cell partnering agreement, with real-world examples
    Stem Cell Partnering Terms and Agreements includes:
    In Global Stem Cell Partnering Terms and Agreements 2010-2021, the available deals are listed by:

CIT GAP Funds Invests in Acomhal to Advance Therapies for Cancer Treatment

Retrieved on: 
Tuesday, June 8, 2021
Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Cloning, Developmental biology, Cancer stem cell, Cancer

In response to these challenges in treating cancer, Acomhal is developing a first-in-class peptide drug that can kill cancer stem cells.

Key Points: 
  • In response to these challenges in treating cancer, Acomhal is developing a first-in-class peptide drug that can kill cancer stem cells.
  • Acomhal believes that we need to do more to treat and prevent cancer, said Samy Lamouille, PhD, Co-Founder and CEO of Acomhal Research.
  • We thank CIT GAP Funds for their support, whose investment is helping us expand our testing and research efforts.
  • CIT GAP Funds investments are overseen by the CIT GAP Funds Investment Advisory Board (IAB).

Allied Corp Expands Cannabis Production and Inventory Capacity

Retrieved on: 
Thursday, June 3, 2021
Asexual reproduction, Branches of biology, Biology, Natural sciences, Plant reproduction, Cloning, Vegetative, Drying, Food drying, Filtration

Also included in this expansion are planned upgrades to electrical and water filtration systems along with expanded drying and packaging capacity.

Key Points: 
  • Also included in this expansion are planned upgrades to electrical and water filtration systems along with expanded drying and packaging capacity.
  • Our production facilities can accommodate 12,000 plants in vegetative stage and 10,000 cloned plants in the propagation stage.
  • With this progress, Allied intends to provide long-standing, consistent supply and demonstrate scale to the international marketplace, said Calum Hughes, CEO of Allied.
  • Allied Corp. is an international heath company with a mission to address todays medical issues by researching, creating and producing targeted health solutions.